2014
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 2014, 83: 134-141. PMID: 24907236, PMCID: PMC4117168, DOI: 10.1212/wnl.0000000000000564.Peer-Reviewed Original ResearchConceptsHigher CPE scoreLower CPE scoreAntiretroviral therapy regimenProgressive multifocal leukoencephalopathyCPE scoreHIV dementiaHazard ratioCryptococcal meningitisMultifocal leukoencephalopathyTherapy regimenAntiretroviral therapy-naive individualsCNS penetration-effectiveness (CPE) scoreTherapy-naive individualsRespective hazard ratiosCases of toxoplasmosisHIV-CAUSAL CollaborationIncidence of AIDSAntiretroviral penetrationAntiretroviral regimenBaseline regimensInitial regimenNeurologic conditionsNeurologic disordersCNS penetrationRegimen
2013
Management of Human Immunodeficiency Virus Infection in Advanced Age
Greene M, Justice AC, Lampiris HW, Valcour V. Management of Human Immunodeficiency Virus Infection in Advanced Age. JAMA 2013, 309: 1397-1405. PMID: 23549585, PMCID: PMC3684249, DOI: 10.1001/jama.2013.2963.Peer-Reviewed Original ResearchConceptsHIV-positive patientsOlder HIV-positive patientsHuman immunodeficiency virus (HIV) infectionHIV-negative counterpartsComorbid medical illnessesHIV-negative patientsComorbid medical conditionsImmunodeficiency virus infectionHuman immunodeficiency virusLife expectancyMultiple comorbid diseasesLonger life expectancyAntiretroviral regimenOlder HIVAntiretroviral therapyComorbid diseasesConcomitant diseasesPositive patientsMedical illnessImmunodeficiency virusAdvanced ageChronic diseasesChronic illnessConsensus statementVirus infection
2010
Virologic and immunologic response to HAART, by age and regimen class
Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, Gill MJ, Lau B, Napravnik S, Tedaldi E, Klein MB, Gebo KA. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010, 24: 2469-2479. PMID: 20829678, PMCID: PMC3136814, DOI: 10.1097/qad.0b013e32833e6d14.Peer-Reviewed Original ResearchConceptsCD4 cell countImmunologic responseNorth American AIDS Cohort CollaborationCell countMean CD4 cell countProtease inhibitor-based regimenNonnucleoside reverse transcriptase inhibitorAntiretroviral-naive adultsInhibitor-based regimenInitial antiretroviral regimenProspective cohort studyConfidence intervalsReverse transcriptase inhibitorImpact of ageInverse probability weightsCohort CollaborationInitial regimenAntiretroviral regimenVirologic responseCohort studyViral loadEligible participantsOdds ratioTranscriptase inhibitorRegimen
2009
HIV infection in the elderly
Gebo KA, Justice A. HIV infection in the elderly. Current Infectious Disease Reports 2009, 11: 246-254. PMID: 19366568, PMCID: PMC3129647, DOI: 10.1007/s11908-009-0036-0.Peer-Reviewed Original ResearchOlder patientsYounger patientsBetter virologic suppressionOlder HIV patientsActive antiretroviral therapyManagement of HIVPrevalence of HIVDrug-drug interactionsAntiretroviral regimenHAART initiationHAART regimenVirologic suppressionAntiretroviral therapyHIV patientsImmunologic benefitsHIV infectionPatientsSide effectsHIVPopulation agesRegimenAgeHAARTComorbiditiesTherapy